News & Updates

Show Multimedia Only

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021 by

Treatment with ixekizumab (IXE) for moderate-to-severe plaque psoriasis is consistently safe and effective through 264 weeks in patients using the approved dose, according to the UNCOVER-3 study.

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

03 Aug 2021

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

New drug applications approved by US FDA as of 16-31 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

02 Aug 2021

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021 by

Patients with psoriasis taking the immunosuppressant methotrexate had low antibody responses to SARS-CoV-2 after receiving the first dose of Pfizer-BioNTech’s BNT162b2 vaccine but had shown T-cell responses, according to a study that was the first to look at T-cell responses in patients taking methotrexate.

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

26 Jul 2021

News & Updates

Showing Dermatology articles

Showing

Specialty:

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Ixekizumab safe, effective up to 5 years in moderate-to-severe plaque psoriasis

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

Original New Drug Application Approvals by US FDA (16 - 31 July 2021)

T-cell responses to BNT162b2 vaccine not weakened by methotrexate

T-cell responses to BNT162b2 vaccine not weakened by methotrexate